Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

Xavier Montalbán; Stephen L. Hauser; Ludwig Kappos; Douglas L. Arnold; Amit Bar‐Or; Giancarlo Comi; J. de Sèze; Gavin Giovannoni; Hans‐Peter Hartung; Bernhard Hemmer; Fred Lublin; Kottil Rammohan; Krzysztof Selmaj; Anthony Traboulsee; Annette Sauter; Donna Masterman; Paulo Fontoura; Shibeshih Belachew; Hideki Garren; Nicole Mairon; Peter Chin; Jerry S. Wolinsky

doi:10.1056/nejmoa1606468

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Among patients with primary progressive multiple sclerosis, ocrelizumab was associated with lower rates of clinical and MRI progression than placebo. Extended observation is required to determine the long-term safety and efficacy of ocrelizumab. (Funded by F. Hoffmann-La Roche; ORATORIO ClinicalTrials.gov number, NCT01194570 .).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Montalbán et al. (2016) studied this question.

synapsesocial.com/papers/69d5764962196bac97d9bac9 https://doi.org/10.1056/nejmoa1606468

View Full Paper

Ask AI

Bookmark

Share

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

Ask about this paper

Abstract

Discussion

Cite This Study

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading